Patents by Inventor Vanessa Voskinarian-Berse
Vanessa Voskinarian-Berse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230142803Abstract: Provided herein are methods of producing natural killer (NK) cells and/or ILC3 cells using a three-stage expansion and differentiation method with media comprising stem cell mobilizing factors. Also provided herein are methods of suppressing tumor cell proliferation using the NK cells and/or ILC3 cells and the NK cell and/or ILC3 cell populations produced by the three-stage methods described herein, as well as methods of treating individuals having cancer or a viral infection, comprising administering the NK cells and/or ILC3 cells and the NK cell and/or ILC3 cell populations produced by the three-stage methods described herein to an individual having the cancer or viral infection.Type: ApplicationFiled: November 16, 2022Publication date: May 11, 2023Applicant: Celularity Inc.Inventors: Xiaokui ZHANG, Ivana DJURETIC, Lin KANG, Vanessa VOSKINARIAN-BERSE, Bhavani STOUT, Robert J. HARIRI, Wolfgang HOFGARTNER, James EDINGER, Eric LAW, Vladimer JANKOVIC
-
Publication number: 20230028680Abstract: Provided herein are methods of producing natural killer (NK) cells and/or ILC3 cells using a three-stage expansion and differentiation method with media comprising stem cell mobilizing factors. Also provided herein are methods of suppressing tumor cell proliferation using the NK cells and/or ILC3 cells and the NK cell and/or ILC3 cell populations produced by the three-stage methods described herein, as well as methods of treating individuals having cancer or a viral infection, comprising administering the NK cells and/or ILC3 cells and the NK cell and/or ILC3 cell populations produced by the three-stage methods described herein to an individual having the cancer or viral infection.Type: ApplicationFiled: November 29, 2019Publication date: January 26, 2023Applicant: Celularity Inc.Inventors: Robert J. HARIRI, Xiaokui ZHANG, Lin KANG, William VAN DER TOUW, Vanessa VOSKINARIAN-BERSE, Xuan GUO
-
Publication number: 20220259563Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.Type: ApplicationFiled: April 29, 2022Publication date: August 18, 2022Applicant: Celularity Inc.Inventors: Robert J. HARIRI, Mohammad A. Heidaran, Stephen Jasko, Lin Kang, Eric Law, Ajai Pal, Bhavani Stout, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
-
Patent number: 11180731Abstract: Provided herein are methods of treating acute myeloid leukemia (AML) and multiple myeloma (MM) by administering an effective amount of a cell population comprising natural killer cells, wherein the cell population comprising natural killer cells is produced by a three-stage method comprising culturing a population of hematopoietic stem or progenitor cells in media comprising stem cell mobilizing factors, e.g., three-stage methods of producing NK cells in media comprising stem cell mobilizing factors starting with hematopoietic stem or progenitor cells from cells of the placenta, for example, from placental perfusate (e.g., human placental perfusate) or other tissues, for example, umbilical cord blood or peripheral blood. Further provided herein are methods of using the NK cells produced by the three-stage methods provided herein to suppress the proliferation of acute myeloid leukemia cells.Type: GrantFiled: May 5, 2017Date of Patent: November 23, 2021Assignee: Celularity Inc.Inventors: Steven A. Fischkoff, Uri Herzberg, Lin Kang, Brian Murphy, Andrea Nordberg, Vanessa Voskinarian-Berse, Keith Wilson, Xiaokui Zhang, Han Myint, Mohamad Hussein, Robert J Hariri
-
Publication number: 20210032596Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.Type: ApplicationFiled: March 12, 2020Publication date: February 4, 2021Applicant: Celularity, Inc.Inventors: Mohammad A. Heidaran, Xiaokui Zhang, Lin Kang, Andrew Zeitlin, Vanessa Voskinarian-Berse, Stewart Abbot
-
Publication number: 20200330516Abstract: Provided herein are methods of producing natural killer (NK) cells using a three-stage expansion and differentiation method with media comprising stem cell mobilizing factors. Also provided herein are methods of suppressing tumor cell proliferation using the NK cells and the NK cell populations produced by the three-stage methods described herein, as well as methods of treating individuals having cancer or a viral infection, comprising administering the NK cells and the NK cell populations produced by the three-stage methods described herein to an individual having the cancer or viral infection.Type: ApplicationFiled: May 18, 2020Publication date: October 22, 2020Applicant: Celularity Inc.Inventors: Brian MURPHY, Vanessa VOSKINARIAN-BERSE, Andrea NORDBERG, Keith WILSON, Lin KANG
-
Publication number: 20190330592Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.Type: ApplicationFiled: July 3, 2019Publication date: October 31, 2019Applicant: Celularity, Inc.Inventors: Robert J. HARIRI, Mohammad A. HEIDARAN, Stephen JASKO, Lin KANG, Eric LAW, Ajai PAL, Bhavani STOUT, Vanessa VOSKINARIAN-BERSE, Andrew ZEITLIN, Xiaokui ZHANG
-
Publication number: 20190153389Abstract: Provided herein are methods of treating acute myeloid leukemia (AML) and multiple myeloma (MM) by administering an effective amount of a cell population comprising natural killer cells, wherein the cell population comprising natural killer cells is produced by a three-stage method comprising culturing a population of hematopoietic stem or progenitor cells in media comprising stem cell mobilizing factors, e.g., three-stage methods of producing NK cells in media comprising stem cell mobilizing factors starting with hematopoietic stem or progenitor cells from cells of the placenta, for example, from placental perfusate (e.g., human placental perfusate) or other tissues, for example, umbilical cord blood or peripheral blood. Further provided herein are methods of using the NK cells produced by the three-stage methods provided herein to suppress the proliferation of acute myeloid leukemia cells.Type: ApplicationFiled: May 5, 2017Publication date: May 23, 2019Applicant: CELULARITY, INC.Inventors: Steven A. FFISCHKOFF, Uri HERZBERG, Lin KANG, Brian MURPHY, Andrea NORDBERG, Vanessa VOSKINARIAN-BERSE, Keith WILSON, Xiaokui ZHANG, Han MYINT, Mohamed HUSSEIN
-
Publication number: 20180346877Abstract: Provided herein are methods of producing natural killer (NK) cells and/or ILC3 cells using a three-stage expansion and differentiation method with media comprising stem cell mobilizing factors. Also provided herein are methods of suppressing tumor cell proliferation using the NK cells and/or ILC3 cells and the NK cell and/or ILC3 cell populations produced by the three-stage methods described herein, as well as methods of treating individuals having cancer or a viral infection, comprising administering the NK cells and/or ILC3 cells and the NK cell and/or ILC3 cell populations produced by the three-stage methods described herein to an individual having the cancer or viral infection.Type: ApplicationFiled: October 14, 2016Publication date: December 6, 2018Applicant: CELULARITY, INC.Inventors: Xiaokui ZHANG, Ivana DJURETIC, Lin KANG, Vanessa VOSKINARIAN-BERSE, Bhavani STOUT, Robert J. HARIRI, Wolfgang HOFGARTNER, James EDINGER, Eric LAW, Vladimir JANKOVIC
-
Patent number: 10041043Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perforate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrate erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.Type: GrantFiled: December 22, 2015Date of Patent: August 7, 2018Assignee: CELULARITY, INC.Inventors: Stewart Abbot, Lin Kang, Vanessa Voskinarian-Berse, Xiaokui Zhang
-
Publication number: 20180008637Abstract: Provided herein are methods of producing natural killer (NK) cells using a three-stage expansion and differentiation method with media comprising stem cell mobilizing factors. Also provided herein are methods of suppressing tumor cell proliferation using the NK cells and the NK cell populations produced by the three-stage methods described herein, as well as methods of treating individuals having cancer or a viral infection, comprising administering the NK ce3lls and the NK cell populations produced by the three-stage methods described herein to an individual having the cancer or viral infection.Type: ApplicationFiled: December 30, 2015Publication date: January 11, 2018Applicant: ANTHROGENESIS CORPORATIONInventors: Brian MURPHY, Vanessa VOSKINARIAN-BERSE, Andrea NORDBERG, Keith WILSON, Lin KANG
-
Patent number: 9763983Abstract: Provided herein are placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, combined natural killer cells from placenta and umbilical cord blood, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, and combined natural killer cells and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells. Also provided herein are methods of treating an individual having a tumor or graft-versus-host disease with placental perfusate, placental perfusate-derived cells, natural killer cells from placenta, e.g., from placental perfusate, and/or combined natural killer cells comprising natural killer cells from placenta, e.g., from placental perfusate, and umbilical cord blood.Type: GrantFiled: February 4, 2014Date of Patent: September 19, 2017Assignee: ANTHROGENESIS CORPORATIONInventors: Xiaokui Zhang, Robert J. Hariri, Vanessa Voskinarian-Berse, Lin Kang, Eric Law, Stewart Abbot
-
Publication number: 20170240860Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.Type: ApplicationFiled: October 28, 2015Publication date: August 24, 2017Applicant: Anthrogenesis CorporationInventors: Mohammad A. Heidaran, Xiaokui Zhang, Lin Kang, Andrew Zeitlin, Vanessa Voskinarian-Berse, Stewart Abbot
-
Publication number: 20170000828Abstract: Provided herein are methods of producing enhanced placental stem cells by modulatory RNA molecules. Also provided herein are methods of using enhanced placental stem cells, for example, to treat individuals having a disease, disorder or condition caused by, or relating to, an unwanted or harmful immune response. Further provided herein are compositions comprising said enhanced placental stem cells.Type: ApplicationFiled: September 22, 2016Publication date: January 5, 2017Applicant: ANTHROGENESIS CORPORATIONInventors: Stewart Abbot, Kathy E. Karasiewicz-Mendez, Vanessa Voskinarian-Berse, Xiaokui Zhang
-
Publication number: 20170002322Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.Type: ApplicationFiled: September 12, 2016Publication date: January 5, 2017Applicant: Anthrogenesis CorporationInventors: Robert J. HARIRI, Mohammad A. HEIDARAN, Stephen JASKO, Lin KANG, Eric LAW, Ajai PAL, Bhavani STOUT, Vanessa VOSKINARIAN-BERSE, Andrew ZEITLIN, Xiaokui ZHANG
-
Publication number: 20160362659Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perforate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrate erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.Type: ApplicationFiled: December 22, 2015Publication date: December 15, 2016Applicant: Anthrogenesis CorporationInventors: Stewart Abbot, Lin Kang, Vanessa Voskinarian-Berse, Xiaokui Zhang
-
Patent number: 9464274Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.Type: GrantFiled: November 18, 2014Date of Patent: October 11, 2016Assignee: Anthrogenesis CorporationInventors: Robert J. Hariri, Mohammad A. Heidaran, Stephen Jasko, Lin Kang, Eric Law, Ajai Pal, Bhavani Stout, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
-
Publication number: 20160287635Abstract: Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.Type: ApplicationFiled: November 16, 2015Publication date: October 6, 2016Applicant: ANTHROGENESIS CORPORATIONInventors: Robert J. Hariri, Mohammad A. Heidaran, Lin Kang, Neerav Dilip Padliya, Ajai Pal, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
-
Patent number: 9255248Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.Type: GrantFiled: October 11, 2013Date of Patent: February 9, 2016Assignee: Anthrogenesis CorporationInventors: Stewart Abbot, Lin Kang, Vanessa Voskinarian-Berse, Xiaokui Zhang
-
Publication number: 20150366910Abstract: Provided herein are placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, combined natural killer cells from placenta and umbilical cord blood, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, and combined natural killer cells and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells. Also provided herein are methods of treating an individual having a tumor or graft-versus-host disease with placental perfusate, placental perfusate-derived cells, natural killer cells from placenta, e.g., from placental perfusate, and/or combined natural killer cells comprising natural killer cells from placenta, e.g., from placental perfusate, and umbilical cord blood.Type: ApplicationFiled: February 4, 2014Publication date: December 24, 2015Inventors: Xiaokui ZHANG, Robert J. HARIRI, Vanessa VOSKINARIAN-BERSE, Lin KANG, Eric LAW, Stewart ABBOT